Category: BiometSyndicate content

Biomet slashes Q3 losses, sales rise nearly 7%

April 3, 2014 by Brad Perriello

Orthopedics bellwether Biomet cuts its 3rd-quarter losses by nearly 80% on a 6.6% sales increase.

Biomet slashes Q3 losses, sales rise nearly 7%

Biomet said today that it slashed its 3rd-quarter losses by nearly 80% and boosted sales by 6.6% as the privately-owned orthopedics giant prepares to go back on the stock market.

Warsaw, Ind.-based Biomet posted losses of -$65.9 million on sales of $822.5 million for the 3 months ended Feb. 28. Adjusted to exclude 1-time items, profits rose 13.1% compared with the same period last year, to $107.3 million.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Biomet puts itself back on public market | Medtech Wall Street news for the week of Mar. 10, 2014

March 13, 2014 by MassDevice staff

Here's a look at some of the top Wall Street stories for medical device companies this week.

Biomet announces IPO plans

March 7, 2014 by Brad Perriello

Biomet announces IPO plans

Biomet is planning to put itself back on the public market after a 7-year run under private equity ownership, the orthopedics giant said today.

Biomet announces IPO plans

March 7, 2014 by Brad Perriello

Biomet's private equity owners announce plans to take the orthopedics giant back on the public market.

Biomet announces IPO plans

Biomet is planning to put itself back on the public market after a 7-year run under private equity ownership, the orthopedics giant said today.

A group of private PE players including the Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts and TPG acquired Biomet for $11.4 billion in 2007, placing medtech veteran Jeffrey Binder at the helm.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Biomet settles M2A Magnum hip implant cases

February 4, 2014 by Brad Perriello

Biomet agrees to settle more than 1,000 product liability lawsuits filed over its M2A Magnum metal-on-metal hip implant.

Biomet settles M2A Magnum hip implant cases

Biomet said it agreed to settle more than 1,000 lawsuits filed over its M2A Magnum hip implants and will likely exhaust the $50 million it set aside to cover the legal tab.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Biomet swings to Q2 black

January 8, 2014 by Brad Perriello

Biomet reports a 2nd-quarter swing to profitability on stronger sales growth for its bread-and-butter knee and hip replacement products.

Biomet swings to Q2 black

Biomet posted fiscal 2nd-quarter profits today, reporting sales growth for its core hip and knee replacement products and gains across the board for its other medical device lines.

The news augurs well for other orthopedic device makers, as Biomet's early quarterly reports are seen on Wall Street as bellwethers for the rest of the industry.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

2013 year in review: Our 5 most-read stories of the year

December 24, 2013 by MassDevice staff

Lawsuits, layoffs, and the medical device tax, oh my! These are the most-read medical device stories of the year from MassDevice.com.

1. Stryker sues Biomet, sales reps over alleged poaching scheme

Stryker sues Biomet, sales reps over alleged poaching scheme

Biomet signs Euro distribution deal with Titan Spine

November 7, 2013 by Chris Walker

Orthopedics giant Biomet will provide European distribution for Titan Spine's Endoskeleton interbody fusion devices.

Titan Spine signs distribution deal with Biomet in Europe

Biomet signed a European distribution deal for Titan Spine's Endoskeleton interbody fusion devices, beginning in Germany and spreading through the E.U., the companies announced.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp